




RealRate

PHARMACEUTICAL 2023

Iterum Therapeutics plc
Rank 324 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Iterum Therapeutics plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Iterum Therapeutics plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Iterum Therapeutics plc is the variable Liabilities, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 74% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	62,444
Cost of Goods Sold	0
Intangible Assets	1,719
Liabilities, Current	9,064
Liabilities, Non-Current	11,398
Other Assets	2,601
Other Compr. Net Income	-350
Other Expenses	301
Other Liabilities	18,372
Other Net Income	-13,750
Other Revenues	0
Property and Equipment	69
Research and Development	17,617
Selling, General and Administrative Expense	12,766

Output Variable	Value in 1000 USD
Assets	66,833
Liabilities	38,834
Expenses	30,684
Revenues	0
Stockholders Equity	27,999
Net Income	-44,434
Comprehensive Net Income	-44,609
BaseVar	75,226
ECR before Limited Liability	31%
Economic Capital Ratio	171%